Tenaya Therapeutics, Inc. Cash and Restricted Cash
Tenaya Therapeutics, Inc. (TNYA) had Cash and Restricted Cash of $78.50 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $78.50M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $81.31M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $100.97M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56.73M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $78.50M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $81.31M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $100.97M 10-K · filed 2026-03-11 |
| 2025-09-30 | $56.73M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $63.09M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $54.19M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $4.74M 10-K · filed 2026-03-11 |
| 2024-09-30 | $8.65M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $58.55M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $59.98M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $46.36M 10-K · filed 2025-03-10 |
| 2023-09-30 | $82.83M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $75.98M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $72.94M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $95.67M 10-K · filed 2024-03-18 |
| 2022-09-30 | $34.89M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $31.41M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $26.37M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $38.68M 10-K · filed 2023-03-08 |
| 2021-09-30 | $117.62M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $112.43M 10-Q · filed 2022-08-10 |
| 2021-03-31 | $128.99M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $129.08M 10-K · filed 2022-03-23 |
| 2020-09-30 | $61.74M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $40.74M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |